ICAAC In Brief: SmithKline Beecham Famvir
Executive Summary
SmithKline Beecham Famvir: Famciclovir delays recurrent episodes of genital herpes in patients with frequently recurring disease who received 250 mg twice-daily doses of the antiviral for one year, according to results from a 455-patient trial presented at ICAAC. Median time to first clinically confirmed lesional episodes for patients treated with Famvir in the study was 11 months compared to 1.5 months for placebo-treated patients. Median time to first culture documented recurrence was more than one year for patients receiving Famvir and 2.7 months for patients on placebo...